Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Minute Insight: NeuroOne Amends Deal With Zimmer Biomet To Shore Up Balance Sheet

Executive Summary

Zimmer Biomet agreed to amend its exclusive development and distribution agreement with NeuroOne to pay $3.5m for 350,000 of stock. The deal will help NeuroOne continue to develop its Evo stereoelectroencephalography brain-mapping electrodes without further diluting the company’s stock.

You may also be interested in...



NeuroOne’s CEO Talks About 510(k) Clearance Of Evo sEEG Electrodes

Medtech Insight spoke to Dave Rosa, CEO of NeuroOne, about working with the FDA to get a 510(k) clearance.

NeuroOne: Thinner Is Better When It Comes To Brain Electrodes

NeuroOne manufactures the thinnest FDA-approved stereoelectroencephalography electrode for 30-day use, and a recent Emory University study could further expand their applications.

Change Of Plan: Medtronic Drops Ventilators, Keeps Monitoring, Forms New Unit

Medtronic will stop producing ventilators and combine the rest of its patient monitoring and respiratory interventions business into a new business called acute care and monitoring. The company had previously announced plans to divest all of the patient monitoring and respiratory intervention business.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT145679

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel